Argos Therapeutics, Inc. (ARGS)
(Delayed Data from OTC)
$0.10 USD
0.00 (0.00%)
Updated Dec 4, 2018 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[ARGS]
Reports for Purchase
Showing records 1 - 20 ( 48 total )
Industry: Medical - Biomedical and Genetics
ValuEngine Detailed Valuation Report for ARGS
Provider: ValuEngine, Inc
Industry: Medical - Biomedical and Genetics
We are dropping coverage of ARGS due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
Investor Day Highlights; Driving Toward Phase III Data in 2Q17
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
ROTH Healthcare Monthly - Longing for Better Blood at ASH
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Healthcare - Innovations in Oncology Corporate Access Day Recap
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
3Q16 Results; A Few Major Answers in the Near Future
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
2Q16 Results; Cash in Hand; Pushing Toward Phase III Data in 1H17
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
1Q16 Results; Next IDMC Look Next Month; Expect Non-Event
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
2015 Results; Cash to Phase III Data and Looking Toward Upcoming Interims
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
Current Shareholders Ante Up To Address Overhang; Target Tweaked to $11
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Industry: Medical - Biomedical and Genetics
No "ADAPTation" as Study Moves Forward; Timelines Unchanged
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J